Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: Impact on metabolism and fertility

Endocrine

Volumn 44, Issue 3, 2013, Pages 583-590

  Panidis, Dimitrios ^a   Tziomalos, Konstantinos ^a   Papadakis, Efstathios ^a   Vosnakis, Christos ^a   Chatzis, Panagiotis ^a   Katsikis, Ilias ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Diet; Exercise; Insulin resistance; Orlistat; Polycystic ovary syndrome; Sibutramine

Indexed keywords

METFORMIN; TETRAHYDROLIPSTATIN;

BEHAVIOR MODIFICATION; DIET THERAPY; DRUG EFFICACY; FEMALE FERTILITY; FOOD COMPOSITION; GASTROINTESTINAL SYMPTOM; HUMAN; LIFESTYLE MODIFICATION; OBESITY; OVARY POLYCYSTIC DISEASE; PHARMACEUTICAL CARE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; DIET; ENERGY METABOLISM; EXERCISE; FEMALE; FERTILITY; HUMANS; LIFE STYLE; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 84890802725     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-9971-5     Document Type: Review

References (72)

1. J.E. Nestler, Metformin for the treatment of the polycystic ovary syndrome. N. Engl. J. Med. 358, 47-54 (2008)
2. D. Panidis, K. Tziomalos, E. Papadakis, I. Katsikis, Infertility treatment in PCOS: lifestyle interventions, medications and surgery, in Polycystic Ovary Syndrome: Novel Insights into Causes and Therapy, ed. by D. Macut, M. Pfeifer, B. Yildiz, E. Diamanti-Kandarakis (Karger, Basel, 2012)
3. B.C. Fauser, B.C. Tarlatzis, R.W. Rebar, R.S. Legro, A.H. Balen, R. Lobo, E. Carmina, J. Chang, B.O. Yildiz, J.S. Laven, J. Boivin, F. Petraglia, C.N. Wijeyeratne, R.J. Norman, A. Dunaif, S. Franks, R.A. Wild, D. Dumesic, K. Barnhart, Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-sponsored 3rd PCOS consensus workshop group. Fertil. Steril. 97, 28-38.e25 (2012)
4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 81, 19-25 (2004)
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 19, 41-47 (2004)
6. S. Franks, Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria. J. Clin. Endocrinol. Metab. 91, 786-789 (2006)
7. R. Azziz, Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J. Clin. Endocrinol. Metab. 91, 781-785 (2006)
8. J.K. Zawadski, A. Dunaif, in Polycystic Ovary Syndrome, ed. by A. Dunaif, J.R. Givens, F.P. Haseltine, G.E. Merriam; in Current Issues in Endocrinology and Metabolism ed. by S.M. Hershman (Blackwell, Boston 1992) pp. 377-384
9. R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H.F. Escobar-Morreale, W. Futterweit, O.E. Janssen, R.S. Legro, R.J. Norman, A.E. Taylor, S.F. Witchel, Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society: the Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 91, 456-488 (2009)
10. F.J. Broekmans, E.A. Knauff, O. Valkenburg, J.S. Laven, M.J. Eijkemans, B.C. Fauser, PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG 113, 1210-1217 (2006)
11. C.K. Welt, J.A. Gudmundsson, G. Arason, J. Adams, H. Palsdottir, G. Gudlaugsdottir, G. Ingadottir, W.F. Crowley, Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J. Clin. Endocrinol. Metab. 91, 4842-4848 (2006)
12. D. Panidis, K. Tziomalos, G. Misichronis, E. Papadakis, G. Betsas, I. Katsikis, D. Macut, Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study. Hum. Reprod. 27, 541-549 (2012)
13. R.S. Legro, D. Driscoll, J.F. Strauss 3rd, J. Fox, A. Dunaif, Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc. Natl. Acad. Sci. U.S.A. 95, 14956-14960 (1998)
14. M.D. Kahsar-Miller, C. Nixon, L.R. Boots, R.C. Go, R. Azziz, Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil. Steril. 75, 53-58 (2001)
15. S. Franks, M.I. McCarthy, K. Hardy, Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int. J. Androl. 29, 278-285; discussion 286-290 (2006)
16. R.J. Norman, D. Dewailly, R.S. Legro, T.E. Hickey, Polycystic ovary syndrome. Lancet 370, 685-697 (2007)
17. S.F. Witchel, S.E. Recabarren, F. González, E. Diamanti-Kandarakis, K.I. Cheang, A.J. Duleba, R.S. Legro, R. Homburg, R. Pasquali, R.A. Lobo, C.C. Zouboulis, F. Kelestimur, F. Fruzzetti, W. Futterweit, R.J. Norman, D.H. Abbott, Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine 42, 526-534 (2012)
18. N.A. Georgopoulos, E. Kandaraki, D. Panidis, Hyperandrogenism in PCOS. in Diagnosis and Management of Polycystic Ovary Syndrome, ed. by N.R. Farid, E. Diamanti-Kandarakis (Springer, New York, 2009), pp. 105-110
19. F. González, C.L. Sia, F.Z. Stanczyk, H.E. Blair, M.E. Krupa, Hyperandrogenism exerts an anti-inflammatory effect in obese women with polycystic ovary syndrome. Endocrine 42, 726-735 (2012)
20. T. Tsilchorozidou, C. Overton, G.S. Conway, The pathophysiology of polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 60, 1-17 (2004)
21. E. Diamanti-Kandarakis, A.G. Papavassiliou, Molecular mechanisms of insulin resistance in polycystic ovary syndrome. Trends Mol. Med. 12, 324-332 (2006)
22. R. Deniz, B. Gurates, S. Aydin, H. Celik, I. Sahin, Y. Baykus, Z. Catak, A. Aksoy, C. Citil, S. Gungor, Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 42, 694-699 (2012)
23. K. Farrell, M.H. Antoni, Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil. Steril. 94, 1565-1574 (2010)
24. L.J. Moran, S.K. Hutchison, R.J. Norman, H.J. Teede, Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst. Rev. 7, CD007506 (2011)
25. M.E. Sastre, M.O. Prat, M.A. Checa, R.C. Carreras, Current trends in the treatment of polycystic ovary syndrome with desire for children. Ther. Clin. Risk Manag. 5, 353-360 (2009)
26. A. Badawy, A. Elnashar, Treatment options for polycystic ovary syndrome. Int. J. Womens Health 3, 25-35 (2011)
27. L.J. Moran, M.L. Misso, R.A. Wild, R.J. Norman, Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update 16, 347-363 (2010)
28. A.M. Clark, W. Ledger, C. Galletly, L. Tomlinson, F. Blaney, X. Wang, R.J. Norman, Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod. 10, 2705-2712 (1995)
29. A.M. Clark, B. Thornley, L. Tomlinson, C. Galletley, R.J. Norman, Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum. Reprod. 13, 1502-1505 (1998)
30. M.M. Huber-Buchholz, D.G. Carey, R.J. Norman, Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J. Clin. Endocrinol. Metab. 84, 1470-1474 (1999)
31. R.L. Thomson, J.D. Buckley, M. Noakes, P.M. Clifton, R.J. Norman, G.D. Brinkworth, The effect of a hypocaloric diet with and without exercise training on body composition, cardiometabolic risk profile, and reproductive function in overweight and obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 93, 3373-3380 (2008)
32. R.L. Thomson, J.D. Buckley, G.D. Brinkworth, Exercise for the treatment and management of overweight women with polycystic ovary syndrome: a review of the literature. Obes. Rev. 12, e202-e210 (2011)
33. R.L. Thomson, J.D. Buckley, S.S. Lim, M. Noakes, P.M. Clifton, R.J. Norman, G.D. Brinkworth, Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. Fertil. Steril. 94, 1812-1816 (2010)
34. K. Marsh, J. Brand-Miller, The optimal diet for women with polycystic ovary syndrome? Br. J. Nutr. 94, 154-165 (2005)
35. H. Farshchi, A. Rane, A. Love, R.L. Kennedy, Diet and nutrition in polycystic ovary syndrome (PCOS): pointers for nutritional management. J. Obstet. Gynaecol. 27, 762-773 (2007)
36. G.U. Liepa, A. Sengupta, D. Karsies, Polycystic ovary syndrome (PCOS) and other androgen excess-related conditions: can changes in dietary intake make a difference? Nutr. Clin. Pract. 23, 63-71 (2008)
37. L.J. Moran, M. Noakes, P.M. Clifton, L. Tomlinson, C. Galletly, R.J. Norman, Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 88, 812-819 (2003)
38. K. Stamets, D.S. Taylor, A. Kunselman, L.M. Demers, C.L. Pelkman, R.S. Legro, A randomized trial of the effects of two types of short-term hypocaloric diets on weight loss in women with polycystic ovary syndrome. Fertil. Steril. 81, 630-637 (2004)
39. K.A. Marsh, K.S. Steinbeck, F.S. Atkinson, P. Petocz, J.C. Brand-Miller, Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome. Am. J. Clin. Nutr. 92, 83-92 (2010)
40. H.H. Mehrabani, S. Salehpour, Z. Amiri, S.J. Farahani, B.J. Meyer, F. Tahbaz, Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study. J. Am. Coll. Nutr. 31, 117-125 (2012)
41. S.E. Kasim-Karakas, R.U. Almario, L. Gregory, R. Wong, H. Todd, B.L. Lasley, Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 89, 615-620 (2004)
42. C.C. Douglas, B.A. Gower, B.E. Darnell, F. Ovalle, R.A. Oster, R. Azziz, Role of diet in the treatment of polycystic ovary syndrome. Fertil. Steril. 85, 679-688 (2006)
43. L.J. Moran, R. Pasquali, H.J. Teede, K.M. Hoeger, R.J. Norman, Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil. Steril. 92, 1966-1982 (2009)
44. A. Tolino, V. Gambardella, C. Caccavale, A. D'Ettore, F. Giannotti, V. D'Antò, C.L. De Falco, Evaluation of ovarian functionality after a dietary treatment in obese women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 119, 87-93 (2005)
45. J. Holte, T. Bergh, C. Berne, L. Wide, H. Lithell, Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 80, 2586-2593 (1995)
46. T.L. Bützow, M. Lehtovirta, R. Siegberg, O. Hovatta, R. Koistinen, M. Seppäla, D. Apter, The decrease in luteinizing hormone secretion in response to weight reduction is inversely related to the severity of insulin resistance in overweight women. J. Clin. Endocrinol. Metab. 85, 3271-3275 (2000)
47. P. Andersen, I. Seljeflot, M. Abdelnoor, H. Arnesen, P.O. Dale, A. Løvik, K. Birkeland, Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 44, 611-616 (1995)
48. H.S. Randeva, K.C. Lewandowski, J. Drzewoski, K. Brooke-Wavell, C. O'Callaghan, L. Czupryniak, E.W. Hillhouse, G.M. Prelevic, Exercise decreases plasma total homocysteine in overweight young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 87, 4496-4501 (2002)
49. B. Bruner, K. Chad, D. Chizen, Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. Appl. Physiol. Nutr. Metab. 31, 384-391 (2006)
50. C. Vigorito, F. Giallauria, S. Palomba, T. Cascella, F. Manguso, R. Lucci, A. De Lorenzo, D. Tafuri, G. Lombardi, A. Colao, F. Orio, Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 92, 1379-1384 (2007)
51. S. Palomba, F. Giallauria, A. Falbo, T. Russo, R. Oppedisano, A. Tolino, A. Colao, C. Vigorito, F. Zullo, F. Orio, Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum. Reprod. 23, 642-650 (2008)
52. J.A. Hawley, Exercise as a therapeutic intervention for the prevention and treatment of insulin resistance. Diabetes Metab. Res. Rev. 20, 383-393 (2004)
53. C.L. Harrison, C.B. Lombard, L.J. Moran, H.J. Teede, Exercise therapy in polycystic ovary syndrome: a systematic review. Hum. Reprod. Update. 17, 171-183 (2011)
54. F. Giallauria, S. Palomba, L. Maresca, L. Vuolo, D. Tafuri, G. Lombardi, A. Colao, C. Vigorito, O. Francesco, Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf.) 69, 792-798 (2008)
55. D.S. Guzick, R. Wing, D. Smith, S.L. Berga, S.J. Winters, Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil. Steril. 61, 598-604 (1994)
56. G.A. Bray, Medical therapy for obesity: current status and future hopes. Med. Clin. North Am. 91, 1225-1253, xi (2007)
57. D. Panidis, D. Farmakiotis, D. Rousso, A. Kourtis, I. Katsikis, G. Krassas, Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil. Steril. 89, 899-906 (2008)
58. M.A. Rubio, M. Gargallo, Isabel Millán, A., Moreno, B.: drugs in the treatment of obesity: sibutramine, orlistat and rimonabant. Public Health Nutr. 10, 1200-1205 (2007)
59. E. Diamanti-Kandarakis, I. Katsikis, C. Piperi, K. Alexandraki, D. Panidis, Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 66, 103-109 (2007)
60. V. Jayagopal, E.S. Kilpatrick, S. Holding, P.E. Jennings, S.L. Atkin, Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 90, 729-733 (2005)
61. A.E. Nieuwenhuis-Ruifrok, W.K. Kuchenbecker, A. Hoek, P. Middleton, R.J. Norman, Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum. Reprod. Update 15, 57-68 (2009)
62. B. Trolle, A. Flyvbjerg, U. Kesmodel, F.F. Lauszus, Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. Hum. Reprod. 22, 2967-2973 (2007)
63. R. Pasquali, A. Gambineri, D. Biscotti, V. Vicennati, L. Gagliardi, D. Colitta, S. Fiorini, G.E. Cognigni, M. Filicori, A.M. Morselli-Labate, Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85, 2767-2774 (2000)
64. P. Moghetti, R. Castello, C. Negri, F. Tosi, F. Perrone, M. Caputo, E. Zanolin, M. Muggeo, Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. 85, 139-146 (2000)
65. J. Lord, R. Thomas, B. Fox, U. Acharya, T. Wilkin, The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome-a randomised, double-blind, placebo-controlled trial. BJOG 113, 817-824 (2006)
66. G. Ladson, W.C. Dodson, S.D. Sweet, A.E. Archibong, A.R. Kunselman, L.M. Demers, N.I. Williams, P. Coney, R.S. Legro, The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil. Steril. 95, 1059-1066.e1-7 (2011)
67. N. Agarwal, S.P. Rice, H. Bolusani, S.D. Luzio, G. Dunseath, M. Ludgate, D.A. Rees, Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. J. Clin. Endocrinol. Metab. 95, 722-730 (2010)
68. J.P. Baillargeon, D.J. Jakubowicz, M.J. Iuorno, S. Jakubowicz, J.E. Nestler, Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil. Steril. 82, 893-902 (2004)
69. T. Tang, J.M. Lord, R.J. Norman, E. Yasmin, A.H. Balen, Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst. Rev. 5, CD003053 (2012)
70. S. Palomba, F. Orio Jr, A. Falbo, F. Manguso, T. Russo, T. Cascella, A. Tolino, E. Carmina, A. Colao, F. Zullo, Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 90, 4068-4074 (2005)
71. M.T. Sheehan, Polycystic ovarian syndrome: diagnosis and management. Clin. Med. Res. 2, 13-27 (2004)
72. A.M. Herriot, S. Whitcroft, Y. Jeanes, A retrospective audit of patients with polycystic ovary syndrome: the effects of a reduced glycaemic load diet. J. Hum. Nutr. Diet. 21, 337-345 (2008)